Chun Fang Xu

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Effectiveness of computational methods in haplotype prediction
    Chun Fang Xu
    Discovery Genetics, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Hum Genet 110:148-56. 2002
  2. ncbi request reprint Identification of a pharmacogenetic effect by linkage disequilibrium mapping
    C F Xu
    Discovery and Pipeline Genetics, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK
    Pharmacogenomics J 4:374-8. 2004
  3. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
  4. ncbi request reprint Detection of genotyping errors by Hardy-Weinberg equilibrium testing
    Louise Hosking
    GlaxoSmithKline Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, UK
    Eur J Hum Genet 12:395-9. 2004
  5. ncbi request reprint Pharmacogenetics to predict drug-related adverse events
    David A Hosford
    Department of Genetics Research, GlaxoSmithKline R and D, Research Triangle Park, North Carolina 27709, USA
    Toxicol Pathol 32:9-12. 2004
  6. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
  7. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011

Detail Information

Publications7

  1. ncbi request reprint Effectiveness of computational methods in haplotype prediction
    Chun Fang Xu
    Discovery Genetics, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Hum Genet 110:148-56. 2002
    ..However, none of the methods was accurate in predicting individual haplotype phases. The EM and the PHASE methods provided better estimates for overall haplotype frequencies than the subtraction method for both genomic regions...
  2. ncbi request reprint Identification of a pharmacogenetic effect by linkage disequilibrium mapping
    C F Xu
    Discovery and Pipeline Genetics, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire, UK
    Pharmacogenomics J 4:374-8. 2004
    ..Our data illustrated that a genome-wide LD scan of 100,000-200,000 SNPs is sufficient to identify a pharmacogenetic association with a drug-induced adverse event...
  3. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
    ..We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways...
  4. ncbi request reprint Detection of genotyping errors by Hardy-Weinberg equilibrium testing
    Louise Hosking
    GlaxoSmithKline Medicines Research Centre, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY, UK
    Eur J Hum Genet 12:395-9. 2004
    ..Consequently, our current high-throughput genotyping system incorporates tests for both assay specificity and deviation from HWE, to minimise the genotype error rate and therefore improve data quality...
  5. ncbi request reprint Pharmacogenetics to predict drug-related adverse events
    David A Hosford
    Department of Genetics Research, GlaxoSmithKline R and D, Research Triangle Park, North Carolina 27709, USA
    Toxicol Pathol 32:9-12. 2004
    ..Together, these studies demonstrate in a stepwise manner the feasibility of using pharmacogenetic approaches to predict DRAEs...
  6. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
    ..The data presented demonstrate the utility of genetic studies to investigate drug-induced liver injury and potentially support its management in patients...
  7. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
    ..However, transaminase elevations have commonly been observed. This 2-stage study sought to identify genetic determinants of alanine transaminase (ALT) elevations in pazopanib-treated white patients with RCC...